Cintirorgon - Celgene/Lycera
Alternative Names: LYC 55716Latest Information Update: 28 Oct 2022
At a glance
- Originator Lycera
- Class Antineoplastics; Benzoxazines; Fluorinated hydrocarbons; Propionic acids; Small molecules; Sulfones
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists; Retinoic acid receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 27 Oct 2020 Phase II development is ongoing in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (Lycera's pipeline, October 2020)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb